PRPO Precipio, Inc. logo

PRPO Precipio, Inc.

Healthcare
$23.80-3.09%ClosedMarket Cap: $42.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

3.00

P/S

1.63

EV/EBITDA

46.55

DCF Value

$-262.02

FCF Yield

1.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

43.3%

Operating Margin

-6.8%

Net Margin

-3.5%

ROE

-6.7%

ROA

-4.4%

ROIC

-10.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$6.3M$-1.4M$
Q4 null$8.0M$526.0K$
FY null$24.0M$-363.0K$
Q3 null$6.2M$-79.0K$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
SANDBERG RICHARD Adirector
SellThu May 21
SANDBERG RICHARD Adirector
SellThu May 21
SANDBERG RICHARD Adirector
SellThu May 21
Valauri Christina Rizopoulosdirector
SellFri Apr 17
Cossman Jeffreydirector
SellFri Apr 17

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.38

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Peers